Curis (CRIS) Revenue & Revenue Breakdown


OverviewOwnershipFinancialsChartTranscripts

Curis Revenue Highlights


Latest Revenue (Y)

$10.02M

Latest Revenue (Q)

$2.55M

Main Segment (Y)

Gross Royalty Revenue

Curis Revenue by Period


Curis Revenue by Year

DateRevenueChange
2023-12-31$10.02M-1.37%
2022-12-31$10.16M-4.57%
2021-12-31$10.65M-1.72%
2020-12-31$10.84M8.31%
2019-12-31$10.00M-4.07%
2018-12-31$10.43M5.35%
2017-12-31$9.90M31.50%
2016-12-31$7.53M-4.46%
2015-12-31$7.88M-19.96%
2014-12-31$9.84M-34.39%
2013-12-31$15.00M-11.61%
2012-12-31$16.97M14.97%
2011-12-31$14.76M-7.73%
2010-12-31$16.00M86.26%
2009-12-31$8.59M2.67%
2008-12-31$8.37M-48.95%
2007-12-31$16.39M9.73%
2006-12-31$14.94M148.83%
2005-12-31$6.00M21.20%
2004-12-31$4.95M-55.17%
2003-12-31$11.05M-39.92%
2002-12-31$18.39M1592.64%
2001-12-31$1.09M8.97%
2000-12-31$997.08K-68.96%
1999-12-31$3.21M-

Curis generated $10.02M in revenue during NA 2023, up -1.37% compared to the previous quarter, and up 96.12% compared to the same period a year ago.

Curis Revenue by Quarter

DateRevenueChange
2024-06-30$2.55M22.05%
2024-03-31$2.09M-22.63%
2023-12-31$2.70M-4.84%
2023-09-30$2.83M28.95%
2023-06-30$2.20M-4.35%
2023-03-31$2.30M-20.44%
2022-12-31$2.89M2.19%
2022-09-30$2.83M18.05%
2022-06-30$2.39M16.33%
2022-03-31$2.06M-34.39%
2021-12-31$3.13M3.16%
2021-09-30$3.04M32.94%
2021-06-30$2.29M4.43%
2021-03-31$2.19M-27.61%
2020-12-31$3.02M10.28%
2020-09-30$2.74M16.19%
2020-06-30$2.36M-12.88%
2020-03-31$2.71M-17.58%
2019-12-31$3.29M15.09%
2019-09-30$2.86M36.39%
2019-06-30$2.09M18.51%
2019-03-31$1.77M-35.86%
2018-12-31$2.75M-3.23%
2018-09-30$2.85M20.74%
2018-06-30$2.36M-4.46%
2018-03-31$2.47M-24.34%
2017-12-31$3.26M33.47%
2017-09-30$2.44M18.58%
2017-06-30$2.06M-3.28%
2017-03-31$2.13M-9.78%
2016-12-31$2.36M34.28%
2016-09-30$1.76M4.70%
2016-06-30$1.68M-2.66%
2016-03-31$1.73M-17.52%
2015-12-31$2.09M2.33%
2015-09-30$2.04M-1.80%
2015-06-30$2.08M25.58%
2015-03-31$1.66M-16.78%
2014-12-31$1.99M12.91%
2014-09-30$1.76M-63.24%
2014-06-30$4.80M273.75%
2014-03-31$1.28M-15.71%
2013-12-31$1.52M-78.84%
2013-09-30$7.20M33.26%
2013-06-30$5.40M520.17%
2013-03-31$871.43K-48.33%
2012-12-31$1.69M191.89%
2012-09-30$577.76K-86.72%
2012-06-30$4.35M-57.98%
2012-03-31$10.36M-26.49%
2011-12-31$14.09M9476.44%
2011-09-30$147.12K-62.55%
2011-06-30$392.87K194.20%
2011-03-31$133.54K33.16%
2010-12-31$100.29K-96.91%
2010-09-30$3.24M3187.21%
2010-06-30$98.63K-99.21%
2010-03-31$12.56M628.34%
2009-12-31$1.72M125.30%
2009-09-30$765.31K1109.73%
2009-06-30$63.26K-98.95%
2009-03-31$6.04M94.46%
2008-12-31$3.10M3479.87%
2008-09-30$86.72K-97.21%
2008-06-30$3.11M50.31%
2008-03-31$2.07M-82.00%
2007-12-31$11.48M-

Curis generated $2.55M in revenue during Q2 2024, up 22.05% compared to the previous quarter, and up 110.84% compared to the same period a year ago.

Curis Revenue Breakdown


Curis Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Gross Royalty Revenue$9.90M$10.28M$10.40M--
Other Revenue--$1.00K$214.00K-
Contra Revenue-$-116.00K$-101.00K$-103.00K-
Royalty--$10.75M$10.72M-
Research And Development, Net----$100.00K

Curis's latest annual revenue breakdown by segment (product or service), as of Dec 23: Gross Royalty Revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19Jun 19Mar 19Dec 18
Gross Royalty Revenue$2.60M$2.70M$2.30M$2.30M$2.90M$2.84M$2.47M$2.06M$3.10M$3.06M$2.35M$2.19M$2.72M$2.45M$2.52M$2.91M$2.14M$2.14M$2.80M-
Contra Revenue----$-14.00K$-18.00K$-81.00K$-3.00K$-19.00K$-63.00K$2.00K$-22.00K$22.00K$-86.00K$-17.00K$-50.00K$-48.00K$-370.00K--
Other Revenue--------$1.00K-$3.00K--$211.00K------

Curis's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Gross Royalty Revenue (100.00%).

Curis Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
ADAPAdaptimmune Therapeutics$60.28M$128.37M
PIRSPieris Pharmaceuticals$42.81M-
CRISCuris$10.02M$2.55M
MREOMereo BioPharma Group$10.00M-
AFMDAffimed$8.28M$155.00K
HSTOHistogen$3.77M$5.00K
CRVSCorvus Pharmaceuticals--
APTOAptose Biosciences--
XFORX4 Pharmaceuticals-$563.00K
PDSBPDS Bio--
DAWNDay One Biopharmaceuticals-$8.19M
INZYInozyme Pharma--
LPTXLeap Therapeutics--
ALRNAileron Therapeutics--
TERNTerns Pharmaceuticals--
ARTLArtelo Biosciences--

CRIS Revenue FAQ


Curis's yearly revenue for 2023 was $10.02M, representing a decrease of -1.37% compared to 2022. The company's yearly revenue for 2022 was $10.16M, representing a decrease of -4.57% compared to 2021. CRIS's yearly revenue for 2021 was $10.65M, representing a decrease of -1.72% compared to 2020.

Curis's quarterly revenue for Q2 2024 was $2.55M, a 22.05% increase from the previous quarter (Q1 2024), and a 15.89% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $2.09M, a -22.63% decrease from the previous quarter (Q4 2023), and a -9.19% decrease year-over-year (Q1 2023). CRIS's quarterly revenue for Q4 2023 was $2.7M, a -4.84% decrease from the previous quarter (Q3 2023), and a -6.62% decrease year-over-year (Q4 2022).

Curis's revenue growth rate for the last 3 years (2021-2023) was -5.88%, and for the last 5 years (2019-2023) was 0.19%.

Curis's revenue streams in c 23 are Gross Royalty Revenue

For the fiscal year ending Dec 23, the largest source of revenue of Curis was Gross Royalty Revenue. This segment made a revenue of $9.9M, representing 100.00% of the company's total revenue.